Profile data is unavailable for this security.
About the company
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
- Revenue in USD (TTM)0.00
- Net income in USD-109.50m
- Incorporated2015
- Employees82.00
- LocationPharvaris NVJ.H. Oortweg 21LEIDEN 2333 CHNetherlandsNLD
- Websitehttps://pharvaris.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Innoviva Inc | 311.59m | 181.39m | 1.01bn | 112.00 | 7.37 | 1.44 | 4.58 | 3.23 | 2.19 | 2.19 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
Liquidia Corp | 15.97m | -107.69m | 1.02bn | 136.00 | -- | 11.81 | -- | 63.86 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.02bn | 267.00 | -- | -- | -- | 2.47 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Cassava Sciences Inc | 0.00 | -47.90m | 1.06bn | 29.00 | -- | 12.16 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
Arcutis Biotherapeutics Inc | 106.39m | -217.42m | 1.08bn | 296.00 | -- | 4.80 | -- | 10.17 | -2.91 | -2.91 | 1.30 | 1.95 | 0.248 | 0.6845 | 4.26 | 359,439.20 | -50.68 | -65.64 | -56.21 | -71.72 | 92.99 | -- | -204.36 | -1,513.03 | 9.61 | -6.52 | 0.4741 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
Silence Therapeutics plc | 33.55m | -44.39m | 1.09bn | 115.00 | -- | 6.20 | -- | 32.37 | -0.39 | -0.39 | 0.2848 | 1.13 | 0.1829 | -- | 5.37 | 291,718.30 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
AbCellera Biologics Inc | 35.79m | -146.90m | 1.10bn | 586.00 | -- | 0.9719 | -- | 30.73 | -0.5056 | -0.5056 | 0.1232 | 3.85 | 0.0242 | -- | 1.32 | 61,071.67 | -9.92 | 6.08 | -10.62 | 6.67 | -- | -- | -410.47 | 24.69 | 7.75 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
Pharvaris NV | 0.00 | -109.50m | 1.11bn | 82.00 | -- | 2.59 | -- | -- | -2.74 | -2.74 | 0.00 | 7.97 | 0.00 | -- | -- | 0.00 | -35.62 | -36.09 | -37.81 | -38.27 | -- | -- | -- | -- | -- | -33.51 | 0.0006 | -- | -- | -- | -32.15 | -- | -- | -- |
Collegium Pharmaceutical Inc | 566.92m | 93.29m | 1.12bn | 197.00 | 16.59 | 5.03 | 4.66 | 1.97 | 2.06 | 2.06 | 12.06 | 6.79 | 0.4869 | 7.07 | 3.20 | 2,877,782.00 | 8.01 | 2.79 | 12.70 | 4.80 | 60.01 | 50.88 | 16.46 | 5.16 | 1.14 | 3.10 | 0.7372 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
Enliven Therapeutics Inc | 0.00 | -79.60m | 1.13bn | 46.00 | -- | 3.53 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
Mirum Pharmaceuticals Inc | 224.00m | -158.56m | 1.19bn | 278.00 | -- | 5.08 | -- | 5.32 | -3.82 | -3.82 | 5.19 | 4.99 | 0.4546 | 4.24 | 5.62 | 848,477.30 | -32.18 | -38.93 | -38.17 | -44.88 | 73.26 | -- | -70.79 | -190.71 | 3.47 | -- | 0.5667 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
Prothena Corporation PLC | 89.25m | -172.40m | 1.22bn | 173.00 | -- | 2.42 | -- | 13.63 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
Data as of May 21 2024. Currency figures normalised to Pharvaris NV's reporting currency: US Dollar USD
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 5.19m | 9.65% |
Viking Global Investors LPas of 31 Mar 2024 | 3.65m | 6.79% |
Commodore Capital LPas of 31 Mar 2024 | 1.73m | 3.21% |
Cormorant Asset Management LPas of 31 Mar 2024 | 1.71m | 3.18% |
EcoR1 Capital, LLCas of 31 Mar 2024 | 900.00k | 1.67% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 757.92k | 1.41% |
Rock Springs Capital Management LPas of 31 Mar 2024 | 752.92k | 1.40% |
Soleus Capital Management LP (Investment Management)as of 31 Mar 2024 | 401.90k | 0.75% |
Sphera Funds Management Ltd.as of 31 Mar 2024 | 392.88k | 0.73% |
LSP Advisory BVas of 31 Dec 2023 | 211.20k | 0.39% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.